Total parietal peritonectomy in primary debulking surgery for advanced ovarian cancer

被引:5
作者
Yokosu, Kota [1 ,2 ]
Tanabe, Hiroshi [1 ,2 ]
Nomura, Shogo [3 ]
Ozone, Hirokazu [1 ]
Saito, Motoaki [1 ]
Takano, Hirokuni [1 ]
Okamoto, Aikou [1 ]
机构
[1] Jikei Univ, Dept Obstet & Gynecol, Sch Med, Minato Ku, 3-19-18 Nishishinbashi, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Dept Gynecol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Dept Biostat, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
来源
GYNECOLOGIC ONCOLOGY REPORTS | 2021年 / 37卷
关键词
Ovarian Cancer; Recurrence; Complete Surgery; Debulking Surgery; Peritonectomy;
D O I
10.1016/j.gore.2021.100805
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The object of this study is to evaluate the clinical safety and efficacy of total parietal peritonectomy (TPP) in primary debulking surgery (PDS) for advanced ovarian cancer. This retrospective single-center study analyzed 16 patients with FIGO stages IIIC-IVB epithelial ovarian cancer who underwent TPP in PDS and achieved macroscopically complete resection between April 2015 and June 2016. The median age of 16 patients was 52.5 years old. 12 were in stage IIIC and 4 were in stage IV. Regarding intraoperative complications, unintended diaphragm perforation was observed in two patients. Regarding postoperative complications (Clavien-Dindo classification grade 3-5) before the adjuvant chemotherapy, lymph cysts occured in 3 patients, intra-abdominal abscess in 3, ileus in 2, pancreatic fistula in 1 and temporary kidney failure in 1. Regarding postoperative complications (grade 3-5) after the initiation of adjuvant chemotherapy, diaphragmatic hernia occured in 1 patient, ileus in 2 and intra-abdominal abscess in 2. Except 1 patient who relapsed approximately one month from surgery and died, the other 15 patients overcamed complications and recovered without problems in daily life. This analysis was conducted 3 years after all patients underwent PDS, with the 3-year progression-free and overall survival of 62.5% (95% confidence interval [CI], 34.9-81.1) and 87.5% (95 %CI, 58.6-96.7), respectively. Based on the above results, TPP in PDS may improve the prognosis compared to previous reports such as LION trial. On the other hand, complications may increase. Therefore, further studies are necessary on its safety and efficacy.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Asian perspective on debulking surgery for advanced ovarian cancer: An E-survey
    Park, Soo Jin
    Lee, Eun Ji
    Lee, Taek Sang
    Wang, Kung-Liahng
    Okamoto, Aikou
    Ochiai, Kazunori
    Kim, Hee Seung
    Kim, Jae-Weon
    EJSO, 2021, 47 (05): : 1111 - 1116
  • [42] Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
    Fotopoulou, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1665 - 1666
  • [43] The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer
    Menderes, Gulden
    Black, Jonathan D.
    Azodi, Masoud
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 899 - 901
  • [44] Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
    Abbas-Aghababazadeh, Farnoosh
    Sasamoto, Naoko
    Townsend, Mary K.
    Huang, Tianyi
    Terry, Kathryn L.
    Vitonis, Allison F.
    Elias, Kevin M.
    Poole, Elizabeth M.
    Hecht, Jonathan L.
    Tworoger, Shelley S.
    Fridley, Brooke L.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
    Rosen, Barry
    Laframboise, Stephane
    Ferguson, Sarah
    Dodge, Jason
    Bernardini, Marcus
    Murphy, Joan
    Segev, Yakir
    Sun, Ping
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (03) : 462 - 467
  • [46] Subtotal Colectomy as Part of Debulking Surgery for Advanced-stage Ovarian Cancer
    Bacalbasa, Nicolae
    Diaconu, Camelia
    Iliescu, Laura
    Dima, Simona
    Bratu, Ovidiu Gabriel
    Cretoiu, Dragos
    Neacsu, Adrian
    Filipescu, Alexandru
    Savu, Cornel
    Balescu, Irina
    IN VIVO, 2020, 34 (05): : 2757 - 2761
  • [47] Management of Advanced Staged Ovarian Cancer in a National Cancer Center: Comparison of the Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
    Kovacevic, Nina
    Skof, Erik
    Cilensek, Ines
    Merlo, Sebastjan
    CURRENT WOMENS HEALTH REVIEWS, 2021, 17 (03) : 267 - 273
  • [48] Advanced Ovarian Cancer Debulking with Bowel Resection
    Toth, George
    Dahma, George
    Nitu, Razvan
    PROCEEDINGS OF SOGR 2018: THE 17TH NATIONAL CONGRESS OF THE ROMANIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY & FIRST ADVANCED COLPOSCOPY COURSE, 2019, : 808 - 811
  • [49] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
    J. Alejandro Rauh-Hain
    Noah Rodriguez
    Whitfield B. Growdon
    A. K. Goodman
    David M. Boruta
    Neil S. Horowitz
    Marcela G. del Carmen
    John O. Schorge
    Annals of Surgical Oncology, 2012, 19 : 959 - 965
  • [50] A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
    May, Taymaa
    Comeau, Robyn
    Sun, Ping
    Kotsopoulos, Joanne
    Narod, Steven A.
    Rosen, Barry
    Ghatage, Prafull
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) : 668 - 674